20699-85-8

Basic information

• Product Name: METHYL 5-AMINO-1-BENZOTHIOPHENE-2-CARBOXYLATE
• Synonyms: METHYL 5-AMINO-1-BENZOTHIOPHENE-2-CARBOXYLATE;ASISCHEM D48912;5-AMINO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID METHYL ESTER;methyl 5-aminobenzo[b]thiophene-2-carboxylate;5-Aminothionaphthene-2-carboxylic acid methyl ester;ethyl 5-aMinobenzo[b]thiophene-2-carboxylate;ethyl thieno[3,2-f]quinoline-2-carboxylate
• CAS NO: 20699-85-8
• Molecular Formula: C₁₀H₉NO₂S
• Molecular Weight: 207.25
• Mol File: 20699-85-8.mol

Chemical Properties

• Melting Point: 178-179 ºC
• Boiling Point: 382.839 °C at 760 mmHg
• Flash Point: 185.334 °C
• Appearance: /
• Density: 1.353 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.601
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.52±0.10(Predicted)
• CAS DataBase Reference: METHYL 5-AMINO-1-BENZOTHIOPHENE-2-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 5-AMINO-1-BENZOTHIOPHENE-2-CARBOXYLATE(20699-85-8)
• EPA Substance Registry System: METHYL 5-AMINO-1-BENZOTHIOPHENE-2-CARBOXYLATE(20699-85-8)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38
• Safety Statements: 22-26-36/37/39
• Hazardous Substances Data: 20699-85-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 5-amino-1-benzothiophene-2-carboxylate is used as a key intermediate in the synthesis of various pharmaceuticals for its potential to contribute to the development of new drugs and bioactive molecules. Its structural versatility allows for the creation of compounds with specific therapeutic targets.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 5-amino-1-benzothiophene-2-carboxylate serves as a building block for the synthesis of agrochemicals, potentially leading to the development of new pesticides or other agricultural chemicals that can improve crop protection and yield.
Used in Antiviral Applications:
Methyl 5-amino-1-benzothiophene-2-carboxylate is studied for its antiviral properties, making it a candidate for use as an antiviral agent in the development of treatments for viral infections.
Used in Anticancer Applications:
Methyl 5-amino-1-benzothiophene-2-carboxylate is also being investigated for its anticancer activities, suggesting its potential use in the development of anticancer drugs that could target and treat various types of cancer.

InChI:InChI=1/C8H6BrNO2/c9-5-1-2-7-6(3-5)10-8(11)4-12-7/h1-3H,4H2,(H,10,11)

Upstream product

• 20699-86-9 methyl 5-nitrobenzo[b]thiophene-2-carboxylate 
• 6361-21-3 2-chloro-5-nitrobenzaldehyde 
• 27996-87-8 2-fluoro-5-nitrobenzaldehye 

Downstream Products

• 292068-77-0 5-((tert-butoxycarbonyl)amino)benzo[b]thiophene-2-carboxylic acid 
• 292069-59-1 4-{[5-(3-tert-butoxycarbonylamino-benzoylamino)-benzo[b]thiophene-2-carbonyl]-amino}-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester 
• 292069-58-0 4-{[5-(4-tert-butoxycarbonylamino-benzoylamino)-benzo[b]thiophene-2-carbonyl]-amino}-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester 
• 910791-67-2 5-phenylacetylamino-benzo[b]thiophene-2-carboxylic acid methyl ester 
• 910791-68-3 5-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-phenyl-propionylamino]-benzo[b]thiophene-2-carboxylic acid methyl ester 
• 20532-43-8 methyl 5-(acetylamino)benzo[b]thiophene-2-carboxylate 
• 98589-46-9 5-aminobenzo[b]thiophene-2-carboxylic acid 
• 103566-21-8 5-(acetylamino)benzo[b]thiophene-2-carboxylic acid 

Relevant articles and documents

1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE

A compound represented by formula (1) (in the formula: ring-D represents a three- to eight-membered hydrocarbon ring; Ra represents an optionally substituted amino C1-6 alkyl group or the like; Rb1 and Rb2 each independently represent a hydrogen atom, a halogen atom, or the like; Rc represents an optionally substituted C6-10 aryl group or the like; Rd represents a hydrogen atom or the like; and ring-Q represents a (hetero)aryl group or the like which may be substituted with a carboxyl group or the like) or a pharmaceutically acceptable salt thereof exhibits an excellent FXIa inhibitory activity, and is useful as a therapeutic agent against thrombosis or the like.

METHOD FOR PROMOTING PLANT GROWTH

The present invention provides a method for promoting plant growth, which comprises treating a plant with at least one compound selected from a group consisting of a compound represented by the following Formula (1): and an agriculturally acceptable salt thereof, provided that a method for promoting plant growth which comprises treating plants with a compound corresponding to any one of the following (1) to (5) and an agriculturally acceptable salt thereof is excluded: (1) 4-(Trifluoromethyl)benzo[b]thiophene-2-carboxylic acid, (2) 5-(Trifluoromethyl)benzo[b]thiophene-2-carboxylic acid, (3) 6-(Trifluoromethyl)benzo[b]thiophene-2-carboxylic acid, (4) 7-(Trifluoromethyl)benzo[b]thiophene-2-carboxylic acid, and (5) Benzo[b]thiophene-2-carboxylic acid.

Hydroxybenzothiophene ketones are efficient pre-mRNA splicing modulators due to dual inhibition of Dyrk1A and Clk1/4

Dysregulated usage of pre-mRNA splicing sites contributes to the progression of cancer, neurodegenerative diseases, and viral infections. Serine/arginine-rich (SR) proteins play major roles in the splice site recognition and are largely regulated by phosp

BENZOTHIOPHENE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS

The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzothiophene containing compounds and methods for their preparation. These compounds may be useful as

PHENYL CARBOXAMIDE AND SULFONAMIDE DERIVATIVES FOR USE AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE

There is provided a compound having Formula (I) R1-Z-R2 Formula (I) wherein R1 is an optionally substituted phenyl ring; R2 is or comprises an optionally substituted aromatic ring; and Z is -X-Y-L- or -Y-X-L- wherein either X is selected from -S(=O)(=O)- and -C(=O)-, and Y is -NR3-; or X is selected from -S(=O)(=O)- and -S-, and Y is -C(R4)(R5)-; L is an optional linker; and R3, R4 and R5 are each independently selected from H and hydrocarbyl; and wherein when R2 comprises the following structural moiety, Formula (II) wherein Q is an atom selected from the group consisting of S, O, N and C; the compound is selected from compounds of the formulae R1-C(=O)-NR3-L-R2; R1-S(=O)(=O)-C(R4)(R5)-L-R2; R1-S-C(R4)(R5)-L-R2; R1-NR3-S(=O)(=O)-L-R2; R1-NR3-C(=O)-L-R2; R1-C(R4)(R5)-S(=O)(=O)-L-R2; and R1-C(R4)(R5)-S-L-R2. These compounds are useful as 11β-hydroxysteriod dehydrogenase inhibitors in the treatment of i.a. diabetes.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Benzoyl and cinnamoyl nitrogen mustard derivatives of benzoheterocyclic analogues of the tallimustine: Synthesis and antitumour activity

A series of benzoyl and cinnamoyl nitrogen mustards tethered to different benzoheterocycles and to oligopyrroles structurally related to netropsin consisting of two pyrrole-amide units and terminating with an amidine moiety have been synthesised and a str

Total synthesis of distamycin A and 2640 analogues: A solution-phase combinatorial approach to the discovery of new, bioactive DNA binding agents and development of a rapid, high-throughput screen for determining relative DNA binding affinity or DNA binding sequence selectivity

The development of a solution-phase synthesis of distamycin A and its extension to the preparation of 2640 analogues are described. Thus, solution-phase synthesis techniques with reaction workup and purification employing acid/base liquid - liquid extractions were used in the multistep preparation of distamycin A (8 steps, 40% overall yield) and a prototypical library of 2640 analogues providing intermediates and final products that are ≥95% pure on conventional reaction scales. The complementary development of a simple, rapid, and high-throughput screen for DNA binding affinity based on the loss of fluorescence derived from displacement of prebound ethidium bromide is disclosed which is applicable for assessing relative or absolute binding affinity to DNA homopolymers or specific sequences (hairpin oligonucleotides). Using hairpin oligonucleotides, this method permits the screening of a library of compounds against a single predefined sequence to identify high affinity binders, or the screening of a single compound against a full library of individual hairpin oligionucleotides to define its sequence selectivity. The combination permits the establishment of the complete DNA binding profile of each member of a library of compounds. Screening the prototypical library provided compounds that are 1000 times more potent than distamycin A in cytotoxic assays (67, IC50 = 29 nM, L1210), that bind to poly[dA]-poly[dT] with comparable affinity, and that exhibit an altered DNA binding sequence selectivity. Several candidates were identified which bound the five-base-pair AT-rich site of the PSA-ARE-3 sequence, and one (128, K = 3.2 x 106 M-1) maintained the high affinity binding (K = 4.5 x 106 M-1) to the ARE-consensus sequence containing a GC base-pair interrupted five-base-pair AT-rich site suitable for inhibition of gene transcription initiated by hormone insensitive androgen receptor dimerization and DNA binding characteristic of therapeutic resistant prostate cancer.